Results 1 to 10 of about 158,005 (297)
Targeted Strategy in Lipid-Lowering Therapy
Biomedicines, 2022 Dyslipidemia is characterized by a diminished lipid profile, including increased level of total cholesterol and low-density lipoprotein cholesterol (LDL-c) and reduced level of high-density lipoprotein cholesterol (HDL-c). Lipid-lowering agents represent
Ezgi Dayar, Olga Pechanova
doaj +4 more sources
Alirocoumab: new perspectives of lipid-lowering therapy
Терапевтический архив, 2017 Alirocoumab (Praluent) is a fully human monoclonal antibody against proprotein covertase subtilisin/kexin type 9 (PCSK9). The data of ODYSSEY Phases II and III clinical trials demonstrate the high efficacy of alirocoumab in lowering the level of low ...
Zh D Kobalava +2 more
doaj +7 more sources
Editorial: New drugs in lipid lowering therapy [PDF]
Frontiers in Cardiovascular MedicineIbadete Bytyçi +2 more
doaj +2 more sources
Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review [PDF]
КардиоСоматика, 2023 The article discusses modern approaches to screening for dyslipidemia and its control, target levels of low-density lipoproteins (LDL), initiation of lipid-lowering therapy depending on the total risk on the Systematic Coronary Risk Evaluation (SCORE ...
Vera N. Larina +4 more
doaj +1 more source
The Future of Lipid-Lowering Therapy [PDF]
Journal of Clinical Medicine, 2019 The recent introduction of inhibitors of proprotein convertase subtilisin/kexin 9 to lower low-density lipoprotein (LDL) cholesterol on top of statins or as monotherapy is rapidly changing the landscape of treatment of atherosclerotic cardiovascular disease (ASCVD).
Zwol, Willemien Van +2 more
openaire +5 more sources
Lipids in Health and Disease, 2020 Background Several studies have investigated the association between non-statin lipid-lowering therapy and regression of atherosclerosis. However, these studies were mostly small and their results were not always robust.
Walter Masson +6 more
doaj +1 more source
BMC Cancer, 2022 Background In aging populations, the number of people with high cholesterol levels is increasing. Appropriate management of high cholesterol levels with drugs such as statins may prevent secondary diseases.
Kyu-Tae Han, Seungju Kim
doaj +1 more source
Topical issues concerning modern lipid-lowering therapy
Consilium Medicum, 2022 Hypercholesterolemia (high levels of atherogenic lipoproteins) is the main modifiable cardiovascular risk factor in most of the populations, including the Russian population.
Andrey V. Susekov
doaj +1 more source
Lipid-lowering Therapies in Myositis
Current Rheumatology Reports, 2020 The use of lipid-lowering therapies in patients with idiopathic inflammatory myopathies (IIM) is complicated and there are no guidelines for diagnosing, monitoring, or treating atherosclerotic cardiovascular disease (ASCVD) in this group of patients.The use of lipid-lowering therapies, especially statins, is recommended in patients with increased risk ...
Marisa C, Mizus, Eleni, Tiniakou
openaire +3 more sources
npj Digital Medicine, 2022 We developed a smartphone application, MyGeneRank, to conduct a prospective observational cohort study (NCT03277365) involving the automated generation, communication, and electronic capture of response to a polygenic risk score (PRS) for coronary artery
Evan D. Muse +22 more
doaj +1 more source